Welcome to our dedicated page for Biocryst Pharmaceuticals news (Ticker: BCRX), a resource for investors and traders seeking the latest updates and insights on Biocryst Pharmaceuticals stock.
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) is a global biotechnology company focused on hereditary angioedema (HAE) and other rare diseases, and its news flow reflects this specialization. Company press releases frequently highlight regulatory milestones, clinical data, commercial performance, and strategic transactions related to its flagship product ORLADEYO® (berotralstat) and its broader rare disease pipeline.
Investors following BCRX news can expect regular updates on ORLADEYO, described as the first oral, once-daily plasma kallikrein inhibitor for prophylaxis to prevent HAE attacks. Recent announcements have covered U.S. Food and Drug Administration approval of an oral pellet formulation for pediatric patients aged 2 to <12 years, interim data from the APeX-P pediatric trial showing early and sustained reductions in attack rates, and presentations at major allergy and immunology congresses on the burden of HAE in children and caregivers.
BioCryst also issues news on its financial outlook and operating performance, including preliminary ORLADEYO net revenue, total revenue guidance that incorporates RAPIVAB® (peramivir injection), and non-GAAP operating expense expectations. These releases often explain how structural changes, such as the sale of the European ORLADEYO business, affect the company’s revenue mix and cost base.
Strategic and corporate developments are another major theme in BCRX news. The company has announced a definitive agreement to acquire Astria Therapeutics, Inc., with updates on regulatory clearances such as early termination of the Hart-Scott-Rodino waiting period and expected closing timelines. Additional news items include leadership changes, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and planned presentations at high-profile investor conferences.
For readers tracking BCRX, this news stream offers insight into BioCryst’s commercial execution in HAE, progress of its rare disease pipeline, evolving capital allocation, and key corporate events. Regularly reviewing these updates can help contextualize movements in BCRX stock and provide a clearer picture of the company’s strategic direction.
BioCryst (Nasdaq:BCRX) will present at the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025 at 12:00 p.m. ET.
The event will be available via a live audio webcast with a replay. Investors can access the live audio and replay in the Investors & Media section at www.biocryst.com.
BioCryst (Nasdaq:BCRX) reported strong Q3 2025 results driven by ORLADEYO: Q3 ORLADEYO net revenue $159.1M (+37% y-o-y), operating income $29.6M (+285% y-o-y) and non-GAAP operating income $51.7M (+107% y-o-y). The company raised FY2025 ORLADEYO revenue guidance to $590–$600M and lowered FY2025 non-GAAP operating expense guidance to $430–$440M. BioCryst completed the sale of its European ORLADEYO business and used proceeds to retire the Pharmakon term loan. A definitive agreement to acquire Astria Therapeutics was signed; the transaction is expected to close in Q1 2026. Pro forma cash at Sept 30, 2025 was $294M.
BioCryst (Nasdaq: BCRX) will present four abstracts at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting in Orlando, Nov 6–10, 2025.
Planned presentations include a second interim analysis from the APeX-P trial evaluating long-term prophylaxis with once-daily oral granule ORLADEYO (berotralstat) in pediatric hereditary angioedema (HAE) patients aged 2 to <12 years, plus three ePosters on psychosocial burden, caregiver impact, and emergency department experiences for young HAE patients.
Individual ePoster sessions are scheduled Nov 7–9, 2025, and all ePosters will be available online on Nov 6, 2025 at 8:00 a.m. ET to registered attendees.
BioCryst (Nasdaq: BCRX) will report third quarter 2025 financial results on Monday, November 3, 2025. Management will host a conference call and live webcast at 8:30 a.m. ET to discuss results and provide a corporate update.
Dial-in numbers are 1-844-481-2942 (U.S.) and 1-412-317-1866 (international). A live webcast and replay will be available in the investors section of the company website at www.biocryst.com.
BioCryst (Nasdaq: BCRX) agreed to acquire Astria Therapeutics (Nasdaq: ATXS) for an implied value of $13.00 per ATXS share and about $700 million enterprise value. The deal combines BioCryst’s oral HAE franchise with Astria’s injectable Phase 3 candidate navenibart, which has pivotal ALPHA-ORBIT topline data expected in early 2027. BioCryst expects to remain non-GAAP profitable and cash flow positive after closing and to be accretive to operating profit in the first full year after navenibart launch. Closing is expected in Q1 2026, subject to approvals; Astria stockholders would own ~15% of the combined company.
BioCryst (Nasdaq: BCRX) announced on October 3, 2025 that its compensation committee granted inducement equity awards to eight newly hired employees.
The package includes 115,000 stock options and 91,450 restricted stock units (RSUs), granted effective October 1, 2025 under Nasdaq Listing Rule 5635(c)(4). Options carry an exercise price of $7.37 (closing price on the grant date), vest in four equal annual installments beginning one year after grant, and have a 10-year term. Awards are subject to the company’s Inducement Equity Incentive Plan and applicable award agreements.
BioCryst Pharmaceuticals (Nasdaq: BCRX) has completed the sale of its European ORLADEYO business to Neopharmed Gentili for $250 million upfront, with potential additional milestones of up to $14 million. The transaction represents a multiple of 5.4x last twelve months sales through June 2025.
Despite the European business divestiture, BioCryst maintains its 2025 revenue guidance of $580-600 million. The company plans to use the proceeds to retire its $199 million Pharmakon term loan. The deal allows BioCryst to focus on its core U.S. market while Neopharmed Gentili will lead European commercialization, retaining the existing European commercial team.
BioCryst Pharmaceuticals (Nasdaq: BCRX) has granted equity-based compensation to nine newly-hired employees as employment inducements. The compensation package includes:
- Stock options to purchase 36,700 shares at $8.29 per share (equal to closing price on grant date)
- Restricted stock units (RSUs) covering 71,400 shares of common stock
Both options and RSUs were granted on September 2, 2025, and will vest in four equal annual installments. The options have a 10-year term and were granted under BioCryst's Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced its upcoming presentation at the Cantor Global Healthcare Conference in New York. The presentation is scheduled for Thursday, September 4, 2025, at 9:45 a.m. ET. Investors can access both the live audio webcast and replay through the Investors & Media section of BioCryst's website.
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced that Dr. Helen Thackray, Chief Research and Development Officer, will depart the company on September 1, 2025, transitioning to an advisory role through year-end. Dr. Thackray, who joined as a board member in 2019 and became R&D chief in 2021, was a finalist in the recent CEO succession process.
Under her leadership, BioCryst achieved significant milestones, including launching the KLK5 inhibitor BCX17725 for Netherton syndrome, advancing the avoralstat program for diabetic macular edema, and bringing the ORLADEYO pediatric program close to market approval. Dr. Thackray is departing to pursue a chief executive leadership opportunity elsewhere.